France Not Retreating from Gilead Sciences
Gilead Sciences has been no stranger to controversy, with complaints about the pricing of its hepatitis c therapy Sovaldi coming in from every corner. Even with the drug's massive market success so far ($2.3 billion in sales in its first full quarter on the market), pushback from governments and payers has been a continuing concern for the stock.
And now, with France announcing a new information-sharing agreement among 14 EU countries, that pushback just got a little harder. In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give their take on the news out of Europe.
Leaked: This coming blockbuster could make even Sovaldi look small
The best investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
The article France Not Retreating from Gilead Sciences originally appeared on Fool.com.David Williamson owns shares of Express Scripts. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Express Scripts and Gilead Sciences. The Motley Fool owns shares of Express Scripts and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.